STVN Stock Overview
Engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Stevanato Group S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.32 |
| 52 Week High | US$36.30 |
| 52 Week Low | US$18.85 |
| Beta | 0.76 |
| 1 Month Change | -28.02% |
| 3 Month Change | -37.65% |
| 1 Year Change | -28.70% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 3.30% |
Recent News & Updates
Stevanato: Destock Pressures, Long-Term Upside
May 29Stevanato Group S.p.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 12
Recent updates
Stevanato: Destock Pressures, Long-Term Upside
May 29Stevanato Group S.p.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 12Stevanato Group S.p.A.'s (NYSE:STVN) Share Price Matching Investor Opinion
May 07Stevanato Group's (NYSE:STVN) Solid Earnings May Rest On Weak Foundations
Mar 15Stevanato: Destocking And Valuation Risk (Rating Downgrade)
Mar 12Is Stevanato Group S.p.A. (NYSE:STVN) Expensive For A Reason? A Look At Its Intrinsic Value
Feb 09Stevanato: Guidance Reiterated And Supportive Revenue Growth
Nov 22Is Stevanato Group S.p.A. (NYSE:STVN) Worth US$31.6 Based On Its Intrinsic Value?
Oct 22Stevanato: Secular Tailwinds In Biologics Support Downstream Demand
Sep 15Stevanato Group: Undeniable Quality, But Lacking Upside
Jun 14Stevanato Group S.p.A. Just Beat EPS By 5.1%: Here's What Analysts Think Will Happen Next
Mar 05Stevanato Group and Transcoject to provide pre-fillable syringe polymer options for pharma
Jan 24There's Reason For Concern Over Stevanato Group S.p.A.'s (NYSE:STVN) Price
Dec 28Stevanato Group Non-GAAP EPS of $0.14 beats by $0.01, revenue of $245.3M in-line
Nov 08An Intrinsic Calculation For Stevanato Group S.p.A. (NYSE:STVN) Suggests It's 49% Undervalued
Aug 01A Look At The Intrinsic Value Of Stevanato Group S.p.A. (NYSE:STVN)
Apr 19Shareholder Returns
| STVN | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 1.8% | -3.4% | -0.6% |
| 1Y | -28.7% | 3.3% | 22.3% |
Return vs Industry: STVN underperformed the US Life Sciences industry which returned 2.5% over the past year.
Return vs Market: STVN underperformed the US Market which returned 21.5% over the past year.
Price Volatility
| STVN volatility | |
|---|---|
| STVN Average Weekly Movement | 8.8% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: STVN's share price has been volatile over the past 3 months.
Volatility Over Time: STVN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 5,635 | Franco Moro | www.stevanatogroup.com |
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines.
Stevanato Group S.p.A. Fundamentals Summary
| STVN fundamental statistics | |
|---|---|
| Market cap | US$5.34b |
| Earnings (TTM) | US$147.73m |
| Revenue (TTM) | US$1.18b |
37.5x
P/E Ratio4.7x
P/S RatioIs STVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STVN income statement (TTM) | |
|---|---|
| Revenue | €1.08b |
| Cost of Revenue | €757.43m |
| Gross Profit | €325.93m |
| Other Expenses | €189.75m |
| Earnings | €136.18m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.50 |
| Gross Margin | 30.09% |
| Net Profit Margin | 12.57% |
| Debt/Equity Ratio | 26.9% |
How did STVN perform over the long term?
See historical performance and comparison